Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Stressgen (VSE: SSB) -- Ignore unavailable to you. Want to Upgrade?

To: nigel bates who wrote (146)	11/14/2000 9:19:49 PM
From: David Culver	Read Replies (1) \| Respond to of 236

Any guesses what this means for Stressgen

To: nigel bates who wrote (146)	11/15/2000 11:14:51 AM
From: Heat Shock	Read Replies (1) \| Respond to of 236

Nigel: I listened to the StressGen conference call and it clarified that the patent revoked was for the use Stress Proteins alone to get an immune response to fight infection and cancer. CEO Korpolinski said (this is from rapidly taken notes): "It is clear to us that Stress Protein fusions [with an antigen] are much more effective for the treatment of these conditions, and, as such, we have no commercial programs in place to use stress proteins alone for the treatment of these conditions. Therefore, we are not interested in the protection of this area." Korpolinski added that StressGen licensed a bundle of patents from the Whitehead institute in 1993 which included the use of stress proteins alone and also stress protein fusions. "Back then we didn't know which was more important. Now we know fusions are the key." So the loss the patent is not material for StressGen. By the way, when speaking, they referred to the product HspE7 as "hispy E7" and even "hispy seven". Heat.